Related Experiment Video
Updated: May 9, 2026
09:12
Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats
Published on: March 17, 2019
DNA polymorphism in the FKBP5 gene affects impulsivity in intertemporal choice
Yoshiya Kawamura1, Taiki Takahashi, Xiaoxi Liu
1Department of Psychiatry, Sakae Seijinkai Hospital, Kanagawa, Japan. yoshiya-tky@umin.ac.jp
Summary
This study links FKBP5 gene variations to reduced impulsivity in financial decisions. A specific FKBP5 single nucleotide polymorphism (SNP) was associated with less delay discounting, suggesting a genetic influence on intertemporal choice.
Area of Science:
- Behavioral neuroscience
- Genetics
- Endocrinology
Background:
- Impulsivity in intertemporal choice is measured as delay discounting.
- FKBP5 gene variations influence glucocorticoid receptor (GR) sensitivity and cortisol levels.
- Higher cortisol levels correlate with lower impulsivity.
Purpose of the Study:
- To investigate the association between FKBP5 single nucleotide polymorphisms (SNPs) and delay discounting behavior.
Main Methods:
- 91 healthy Japanese participants completed the monetary choice questionnaire (MCQ).
- Five FKBP5 SNPs were genotyped.
- Linear regression analyses were performed to assess the relationship between SNPs and the hyperbolic time-discount rate (k).
Main Results:
- The SNP rs1360780 showed a significant association with delay discounting.
- Participants with more minor alleles (T) at rs1360780 exhibited less impulsivity for delayed rewards (P = 0.047).
Conclusions:
- The minor allele (T) of FKBP5 SNP rs1360780 may reduce impulsivity in intertemporal choice.
- This effect might be mediated by FKBP5 overexpression, leading to GR resistance and elevated cortisol levels.
- This is the first study to establish a link between FKBP5 and impulsivity in intertemporal choice.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:28Human Genetics
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:21Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...